Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by GIBSON, T.
Right arrow Articles by GRAHAME, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by GIBSON, T.
Right arrow Articles by GRAHAME, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1983 British Society for Rheumatology

research-article

CYCLOFENIL TREATMENT OF SCLERODERMA—A CONTROLLED STUDY

T. GIBSON and R. GRAHAME

Department of Rheumatology, Guy's Hospital London SE1 9RT

Correspondence to: Address correspondence to Dr. T. Gibson

A double-blind cross-over study of cyclofenil and placebo treatments was conducted in 11 scleroderma patients. Each treatment period was for four months. A range of subjective and objective measurements failed to reveal any consistent or obvious response to cyclofenil. One patient died of his disease during active treatment. Four were withdrawn because of liver dysfunction which was attributed to cyclofenil. It remains to be seen whether treatment over longer periods will exert a clinically significant effect.

KEY WORDS: Scleroderma, Cyclofenil


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
D. E. Furst, P. J. Clements, W. K. Wong, M. D. Mayes, F. Wigley, B. White, M. Weisman, W. Barr, L. Moreland, R. Martin, et al.
Effects of the American College of Rheumatology systemic sclerosis trial guidelines on the nature of systemic sclerosis patients entering a clinical trial
Rheumatology, June 1, 2001; 40(6): 615 - 622.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.